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Introduction
The following abstracts are part of an ongoing
series of articles produced by the Cochrane
Collaborative Review Group on Peripheral Vascular
Diseases, which is part of the Cochrane Collabor-
ation. The reviews are published in full on The
Cochrane Library, a quarterly electronic journal
available on CD-ROM and via the Internet. The
electronic format allows Cochrane reviews to
accommodate new data as they become available,
making the library a consistently up-to-date source
of information over time.
Certain abstracts appearing on The Cochrane Library
may be presented in a simpler, less scientific format
than the abstract presented here to permit greater
accessibility to the public. However, the substance of
both versions is the same. Cochrane reviews are now
indexed on MEDLINE.
If you are interested in conducting a Cochrane
review or contributing to the activities of the
Cochrane Peripheral Vascular Diseases Group
please contact:
Professor FGR Fowkes






Tel.: þ44-(0)-131-650-3220; fax: þ44-(0)-131-650-6904
Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
criticisms facility on The Cochrane Library, or by contact-
ing the group at the above address.
Abstracts
Abstract. Antiplatelet agents for preventing throm-
bosis after peripheral arterial bypass surgery.
J. Do¨rffler-Melly, H.R. Bu¨ller, M.M. Koopman, M.H.
Prins
Date of most recent substantive amendment: 31 March
2003
Background
Peripheral arterial disease (PAD) may cause occlu-
sions in the main arteries of the lower limbs. It is
frequently treated by implantation of either an infra-
inguinal autologous venous or artificial graft. A
number of factors influence occlusion rates, including
the material used. To prevent graft occlusion, patients
are usually treated with either an antiplatelet or
antithrombotic drug, or a combination of both.
Objectives
To evaluate whether antiplatelet treatment in patients
with symptomatic PAD undergoing infrainguinal
bypass surgery improves graft patency, limb salvage
and survival.
Search strategy
The reviewers searched the Cochrane Peripheral Vas-
cularDiseasesGroupSpecialisedRegister, (last searched
April 2003), and the Cochrane Central Register of
Controlled Trials (CENTRAL) (last searched Issue 1,
2003). Additional trials were sought through reference
lists of papers and by reviewing proceedings from
vascular surgical society meetings.
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Selection criteria
The methodological quality of each trial was assessed
independently by two reviewers with emphasis on
concealment of randomisation.
Data collection and analysis
Details of the studies selected were extracted inde-
pendently by two reviewers and an ’intention-to-treat’
analysis performed. The treatment and control groups
were compared for important prognostic factors and
differences described. If any data were not available,
further information was sought from the author. Data
were synthesized by comparing group results.
Main results
The administration of a variety of platelet-inhibitors
resulted in improved venous and artificial graft
patency compared to no treatment. However, analys-
ing patients for graft-type indicated that patients
receiving a prosthetic graft were more likely to profit
from administration of platelet-inhibitors than those
treated with a venous graft.
Reviewers’ conclusions
Antiplatelet therapy with aspirin had a slight ben-
eficial effect on the patency of peripheral bypasses, but
seemed to have an inferior effect on venous graft
patency compared with artificial grafts. The effect of
aspirin on cardiovascular outcomes and survival was
mild and not statistically significant; this might be due
to the fact that the majority of patients receiving a
peripheral graft have an advanced stage of PAD with
critical ischemia. These patients are usually seriously
ill with respect to cardiovascular diseases with high
mortality rates of 20% per year. Additionally, the
number of patients included in this analysis might still
be too small to reach a statistically significant effect for
mortality and cardiovascular morbidity.
Abstract. Antithrombotic agents for preventing
thrombosis after infrainguinal arterial bypass
surgery.
J. Do¨rffler-Melly, H.R. Bu¨ller, M.M. Koopman, M.H.
Prins
Date of most recent substantive amendment: 2 December
2002
Background
Peripheral arterial disease (PAD) is frequently treated
by either an infrainguinal autologous or artificial graft.
The rate of occlusion after one year is between 15 and
75%. To prevent occlusion, patients are treated with an
antiplatelet or antithrombotic drug, or a combination
of both. Little is known about which drug is optimal to
prevent infrainguinal graft occlusion.
Objectives
To evaluate whether antithrombotic treatment
improves graft patency, limb salvage and survival in
patients with chronic PAD undergoing infrainguinal
bypass surgery.
Search strategy
The search strategy was that adopted by the Cochrane
Review Group on Peripheral Vascular Diseases.
Reference lists of papers resulting from the searches
were also reviewed.
Selection criteria
Two reviewers independently assessed methodologi-
cal quality of each trial using a standardised checklist,
with emphasis on concealment of randomisation.
Data collection and analysis
An ’intention to treat’ analysis was performed. Data
collected included patient details, inclusion and
exclusion criteria, type of graft, antithrombotic
therapy, outcomes, and side effects. Treatment and
control groups were compared for important prog-
nostic factors and differences described. Missing data
were sought from trial authors. Heterogeneity
between trials could not be tested due to inaccessible
data. Data were synthesized by comparing group
results.
Main results
Four trials evaluating vitamin K antagonists (VKA)
versus no VKA indicated that oral anticoagulation
may favour venous but not artificial graft patency, as
well as limb salvage and survival. Two other studies
comparing VKAwith aspirin or aspirin/dipyridamole
supported evidence for a positive effect of VKA on the
patency of venous but not artificial grafts. Subgroup
analysis for artificial grafts as performed in one trial
showed a favourable effect of antiplatelet agents on
synthetic bypasses. In two trials, a small number of
patients treated with low molecular weight heparin
showed a lower incidence of early postoperative graft
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thrombosis compared to unfractionated heparin. In
one trial, infusion of antithrombin concentrate was
reported to have a negative effect on intraoperative
graft thrombosis requiring the study to be stopped
before completion. Perioperative administration of
ancrod showed no greater benefit when compared to
unfractionated heparin.
Reviewers’ conclusions
Patients undergoing infrainguinal venous graft pro-
cedures might benefit from treatment with VKA,
whereas patients receiving an artificial graft might
profit more from platelet inhibitors (aspirin). How-
ever, the evidence is not conclusive. Randomised
controlled trials with larger patient numbers compar-
ing antithrombotic therapies with either placebo or
antiplatelet therapies are needed in the future.
Abstract. Balloon angioplasty versus medical
therapy for hypertensive patients with renal artery
obstruction
A.J. Nordmann, A.G. Logan
Date of most recent substantive amendment: 3 May 2003
Background
Atherosclerotic renal artery stenosis is the most
common cause of secondary hypertension. Balloon
angioplasty is widely used for the treatment of
hypertensive patients with renal artery stenosis.
Objectives
To compare the effectiveness of balloon angioplasty
(with and without stenting) with medical therapy on
blood pressure control, renal function, frequency of
renovascular complications, and side effects in hyper-
tensive patients with atherosclerotic renal artery
stenosis.
Search strategy
MEDLINE, EMBASE, Science Citation Index, the
Cochrane Central Register of Controlled Trials, and
personal files were searched to identify randomised
controlled trials (RCTs) comparing balloon angio-
plasty with medical therapy in hypertensive patients
with renal artery stenosis. Bibliographies resulting
from the searches were also reviewed, and authors of
published trials were contacted for more information.
Selection criteria
RCTs comparing balloon angioplasty with medical
therapy in hypertensive patients with haemodynami-
cally significant renal artery stenosis (greater than 50
per cent reduction in luminal diameter) and minimal
follow-up of six months).
Data collection and analysis
Two investigators independently extracted data on
trial design, participants, interventions, and outcome
measures. Data quality precluded a formal meta-
analysis to assess the effect on blood pressure, renal
function, number and defined daily doses of anti-
hypertensive drugs. Peto’s odds ratios (OR), and
corresponding 95% confidence intervals (CI) were
calculated for dichotomous outcomes, e.g. vessel
patency and renovascular complications.
Main results
Three RCTs involving 210 patients met the inclusion
criteria. In unselected patients there was a consistent,
but statistically non significant trend towards lower
blood pressure in the balloon angioplasty group.
Patients treated with balloon angioplasty required
less antihypertensive drugs in two trials, and were
more likely to have patent renal arteries after 12
months (OR 4.2, 95% CI 1.8 to 9.8). There were no
differences in renal function. There were significantly
fewer cardiovascular and renovascular complications
in patients treated with angioplasty (OR 0.32, 95% CI
0.15 to 0.70, test for heterogeneity p . 0:1).
Reviewers’ conclusions
Available data are insufficient to conclude that balloon
angioplasty is superior to medical therapy in lowering
blood pressure of patients with renal artery stenosis
and pharmacologically controlled blood pressure.
Where hypertension is refractory to medical therapy,
there is weak evidence that balloon angioplasty lowers
blood pressure more effectively than medical therapy.
Balloon angioplasty appears to be safe and shows
fewer cardiovascular and renovascular complications.
Randomised controlled trials are needed to compare
the effect of balloon angioplasty and medical therapy
on the preservation of renal function in the long term.
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Abstract. Spinal cord stimulation for non-recon-
structable chronic critical leg ischaemia
D.T. Ubbink, H. Vermeulen
Date of most recent substantive amendment: 8 April
2003
Background
Patients suffering from inoperable chronic critical leg
ischaemia (NR-CCLI), face amputation of the leg.
Spinal cord stimulation (SCS) has been proposed as a
helpful treatment in addition to standard conservative
treatment.
Objectives
To find evidence for an improvement of limb salvage,
pain relief and clinical situation using SCS compared
to conservative treatment alone.
Search strategy
The reviewers searched the Cochrane Peripheral
Vascular Diseases Group Specialised Register, (last
searched November 2002), the Cochrane Central
Register of Controlled Trials (CENTRAL) (last
searched Issue 4, 2002). Additional data were obtained
from research institutes.
Selection criteria
Controlled studies comparing additional SCS with any
form of conservative treatment in patients with NR-
CCLI.
Data collection and analysis
Two reviewers independently assessed the quality of
the studies and extracted the data.
Main results
Six studies comprising nearly 450 patients were
included. In general the quality of the studies was
good, although none of them was blinded due to the
nature of the intervention.
Limb salvage after 12 months was significantly
higher in the SCS group (risk ratio (RR) 0.71, 95%
confidence intervals (CI) 0.56 to 0.90; risk difference
(RD) 20.13, 95% CI 20.22 to 20.04). Significant pain
relief occurred in both treatment groups, but was more
prominent in the SCS group, in which the patients
required significantly less analgesics. In the SCS group
significantly more patients reached Fontaine stage II
than in the conservative group (RR 4.9, 95% CI 2.0 to
11.9; RD 0.33, 95% CI 0.19 to 0.47). Overall, no
significantly different effect on ulcer healing was
observed between the two treatments.
Complications of SCS treatment consisted of
implantation problems (9%; 95% CI 4 to 15%) and
changes in stimulation requiring re-intervention,
(15%; 95% CI 10 to 20%). Infections of the lead or
pulse generator pocket occurred less frequently (3%;
95% CI 0 to 6%). The overall risk of complications of
additional SCS treatment was 17%, 95% CI 12 to 22%,
indicating a number needed to harm of six (95% CI
5 to 8).
A cost comparison was made in only one study. The
average overall costs at two years were 36,500 Euros,
(SCS group) and 28,600 Euros, (conservative group).
The difference (7900 Euros) was significant ðp , 0:009Þ:
Reviewers’ conclusions
There is evidence to favour SCS over standard
conservative treatment to improve limb salvage and
clinical situation in patients with NR-CCLI. The
benefits of SCS against the possible harm of relatively
mild complications, and costs must be considered.
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